Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report

Brizzi EVD, Argenziano G, Brancaccio G, Scharf C, Ronchi A, Moscarella E. The current clinical approach to difficult-to-treat basal cell carcinomas. Exp Rev Anticancer Ther. 2023;23(1):43–56. DOI: https://doi.org/10.1080/14737140.2023.2161517

https://doi.org/10.1080/14737140.2023.2161517 DOI: https://doi.org/10.1080/14737140.2023.2161517

Guthrie TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–6. DOI: https://doi.org/10.1200/JCO.1990.8.2.342

https://doi.org/10.1200/JCO.1990.8.2.342 DOI: https://doi.org/10.1200/JCO.1990.8.2.342

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9. DOI: https://doi.org/10.1056/NEJMoa1113713

https://doi.org/10.1056/NEJMoa1113713 DOI: https://doi.org/10.1056/NEJMoa1113713

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48. DOI: https://doi.org/10.1016/j.ejca.2017.08.022

https://doi.org/10.1016/j.ejca.2017.08.022 DOI: https://doi.org/10.1016/j.ejca.2017.08.022

Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL. Eribulin in advanced liposarcoma and leiomyosarcoma. Exp Rev Anticancer Ther. 2017;17(8):717–23. DOI: https://doi.org/10.1080/14737140.2017.1344098

https://doi.org/10.1080/14737140.2017.1344098 DOI: https://doi.org/10.1080/14737140.2017.1344098

Goodson HV, Jonasson EM. Microtubules and microtubule-associated proteins. Cold Spring Harb Perspect Biol. 2018;10(6):a022608. DOI: https://doi.org/10.1101/cshperspect.a022608

https://doi.org/10.1101/cshperspect.a022608 DOI: https://doi.org/10.1101/cshperspect.a022608

Čermák V, Dostál V, Jelínek M, Libusová L, Kovář J, Rösel D, et al. Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol. 2020;99(4):151075. DOI: https://doi.org/10.1016/j.ejcb.2020.151075

https://doi.org/10.1016/j.ejcb.2020.151075 DOI: https://doi.org/10.1016/j.ejcb.2020.151075

Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848–57. DOI: https://doi.org/10.1016/S1470-2045(21)00126-1

https://doi.org/10.1016/S1470-2045(21)00126-1 DOI: https://doi.org/10.1016/S1470-2045(21)00126-1

Spann AL, Yuan K, Goliwas KF, Steg AD, Kaushik DD, Kwon YJ, et al. The presence of primary cilia in cancer cells does not predict responsiveness to modulation of smoothened activity. Int J Oncol. 2015;47(1):269–79. DOI: https://doi.org/10.3892/ijo.2015.3006

https://doi.org/10.3892/ijo.2015.3006 DOI: https://doi.org/10.3892/ijo.2015.3006

Martin‐Poch A, Quintana‐Codina M, Ceravalls J, Arandes‐Marcocci J, Iglesias‐Sancho M, Melé‐Ninot G, et al. Tirbanibulin 1% ointment for the treatment of superficial basal cell carcinoma: a retrospective study. J Eur Acad Dermatol Venereol. 2025 Jul 14. Epub ahead of print.. DOI: https://doi.org/10.1111/jdv.20844

https://doi.org/10.1111/jdv.20844 DOI: https://doi.org/10.1111/jdv.20844

Yang N, Leung ELH, Liu C, Li L, Eguether T, Yao XJJ, et al. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma. Oncogene. 2017;36(35):4997–5005. DOI: https://doi.org/10.1038/onc.2017.117

https://doi.org/10.1038/onc.2017.117 DOI: https://doi.org/10.1038/onc.2017.117

Pellacani G, Schlesinger T, Bhatia N, Berman B, Lebwohl M, Cohen JL, et al. Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: data from two phase‐III trials and the real‐life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. J Eur Acad Dermatol Venereol. 2024;38(S1):3–15. DOI: https://doi.org/10.1111/jdv.19636

https://doi.org/10.1111/jdv.19636 DOI: https://doi.org/10.1111/jdv.19636